Burden of illness of diabetic macular edema: literature review

Er, Chen; Looman, Mark; Laouri, Marianne; Gallagher, Meghan; Nuys, Karen Van; Lakdawalla, Darius N.; Fortuny, Joan

doi:10.1185/03007995.2010.482503

Cited by 129 publications

(107 citation statements)

References 44 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…2 DME mostly affects the working-age population, imposing a significant burden both on society and on individual patients 3 Fa burden that is expected to increase with the rising prevalence of diabetes. [4][5][6] The standard therapy for visual impairment due to DMEFfocal and/or grid laser photocoagulation 7,8 Fis mostly only able to stabilise vision.…”

Section: Introductionmentioning

confidence: 99%

New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel

Bandello¹,

Cunha-Vaz

Chong

et al. 2012

Eye

110

View full text Add to dashboard Cite

The current standard therapy for patients with diabetic macular oedema (DME)Ffocal/grid laser photocoagulationFusually does not improve impaired vision, and many patients lose vision despite laser therapy. Recent approval of ranibizumab by the European Medicines Agency to treat visual impairment due to DME fulfils the previously unmet medical need for a treatment that can improve visual acuity (VA) in these patients. We reviewed 1-and 2-year clinical trial findings for ranibizumab used as treatment for DME to formulate evidence-based treatment recommendations in the context of this new therapy. DME with or without visual impairment should be considered for treatment when it fulfils the Early Treatment Diabetic Retinopathy Study (ETDRS) criteria for clinically significant oedema. For DME with centre involvement and associated vision loss due to DME, monthly ranibizumab monotherapy with treatment interruption and re-initiation based on VA stability is recommended. Laser therapy based on ETDRS guidelines is recommended for other forms of clinically significant DME without centre involvement or when no vision loss has occurred, despite centre involvement. Because these recommendations are based on randomised controlled trials of 1-2 years duration, guidance may need updating as long-term ranibizumab data become available and as additional therapeutic agents are assessed in clinical trials.

show abstract

Section: Introductionmentioning

confidence: 99%

New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel

Bandello¹,

Cunha-Vaz

Chong

et al. 2012

Eye

110

View full text Add to dashboard Cite

show abstract

“…With regard to the socioeconomic burden of the disease, DME can lead to visual impairment (VI) with consequent reduction in quality of life and patients with DME consume significantly more healthcare resources than diabetic patients without retinal complications (16) .…”

Section: Discussionmentioning

confidence: 99%

The Effect of Aflibercept and Ranibizumab in Patients with Diabetic Macular Edema: A comparative Study

Eid

Hamed²,

Hudieb³

2018

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Diabetic macular edema is one of the most significant causes of blindness and severe visual impairment in patients with diabetes, which can result in reduced quality of life. Three commonly used intravitreous VEGF inhibitors aflibercept, bevacizumab and ranibizumab have been shown to be beneficial and relatively safe for the treatment of diabetic macular edema, but only aflibercept and ranibizumab are approved by the Food and Drug Administration (FDA) for this indication. Aim of the Work: To compare between the effect of ranibizumab and aflibercept in patients with diabetic macular edema as a diabetic retinopathy complication that leads to visual impairment. Patients and Methods: A prospective study of 20 patients (20 eyes) was conducted in Al-Mouneer diabetic eye center with three times injection one month apart. The patients were divided into two groups, Group A was consisted of 10 patients who received ranibizumab as 0.5 mg (0.05ml of 10mg/ml solution) an intra vitreal injection. Group B was consisted of 10 patients who received aflibercept 2 mg (0.05mL of 40mg/ml solution) as an intra vitreal injection with follow up for three months. Results: A statistically significant difference over the time through BCVA and central macular thickness with ranibizumab. There was also a statistically significant difference over the time through BCVA, central macular thickness and IOP with aflibercept. Conclusion: There was more improvement in BCVA which was significant and more reduction in central macular thickness with ranibizumab than with aflibercept. Recommendations: Larger group studies to confirm our results; longer term study for the effect of ranibizumab and aflibercept injection on the central macular thickness and IOP and comparing the effect of single injection versus multiple injections. Searching for the causes of resistance or delayed response to the intravitreal injections in some patients.

show abstract

“…Die Prävalenz von Diabetes in der Bevölke-rung steigt rapide [2], daher wird das Auftreten von DMÖ schon im erwerbsfähigen Alter in naher Zukunft ein zunehmendes Problem darstellen [3]. DMÖ ist eine potenziell zum Verlust des Sehvermögens führende Komplikation, die ein frühzeitiges therapeutisches Eingreifen erfordert -über 50% aller unzureichend behandelten Patienten büßen in wenigen Jahren Sehschärfe von mehreren Zeilen auf der Sehprobentafel ein [4].…”

Section: Introductionunclassified

Aktuelles zu intravitrealen Steroiden in der Behandlung des diabetischen Makulaödems

Bandello¹,

Preziosa²,

Querques³

et al. 2015

Kompass Ophthalmol

View full text Add to dashboard Cite

Das diabetische Makulaödem gilt als Hauptursache für Visusverschlechterungen bei Patienten mit diabetischer Retinopathie. Neben der Grid- und der fokalen Laser-Koagulation zählt die intravitreale Pharmakotherapie heute zum Therapiestandard bei dieser Komplikation; hierbei werden derzeit Wirkstoffe gegen den vaskulären endothelialen Wachstumsfaktor sowie Steroide eingesetzt. Anders als bei der Laser-Therapie, die eine weitere Abnahme des Sehvermögens verhindert, ist es mit der intravitrealen Behandlung möglich, die Wiederherstellung des Sehvermögens zu fördern. Allerdings müssen intravitreale Injektionen häufig wiederholt werden, wodurch das Risiko für arzneimittel- und behandlungsassoziierte Nebenwirkungen steigt.

show abstract

Burden of illness of diabetic macular edema: literature review

Abstract: There remains a need for consistent data capture and assessment within and between countries included in this analysis. Despite the limited evidence, DME appears to be a costly disease that has a negative impact on patients' quality of life.

Cited by 129 publications

References 44 publications

New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel

New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel

The Effect of Aflibercept and Ranibizumab in Patients with Diabetic Macular Edema: A comparative Study

Aktuelles zu intravitrealen Steroiden in der Behandlung des diabetischen Makulaödems

Contact Info

Product

Resources

About